Beta Bionics Q2 sales beat estimates on pharmacy channel growth
Beta Bionics Q2 sales beat estimates on pharmacy channel growth
Overview
Diabetes device maker's Q2 net sales rose 38% yr/yr, beating analyst expectations
Q2 adjusted EBITDA loss widened yr/yr but was narrower than analyst expectations
Company improved gross margin to 59% and maintained full-year revenue guidance
Outlook
Company sees 2026 revenue of $131 mln to $136 mln, unchanged from prior guidance
Company raises 2026 gross margin outlook to 58.5%-59.5% from 57.5%-59.5%
Beta Bionics expects to fully commercialize Mint patch pump by end of Q2 2027, pending FDA clearance
Result Drivers
PBP CHANNEL GROWTH - Co said PBP channel net sales rose 153% yr/yr, contributing to overall revenue growth
NEW PATIENT STARTS - Co reported new patient starts increased by at least 10% but less than 20% sequentially vs Q1 2026, with 69% coming from multiple daily injections
GROSS MARGIN IMPROVEMENT - Co reported gross margin of 59.0%, up 524 basis points yr/yr
Company press release: ID:nGNX1wM14j
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net sales | Beat | $32.01 mln | $31.44 mln (10 Analysts) |
Q2 Loss Per Share |
| $0.53 |
|
Q2 Net Loss |
| $23.40 mln |
|
Q2 Adjusted EBITDA | Beat | -$17.66 mln | -$21.80 mln (7 Analysts) |
Q2 Income from Operations | Beat | -$25.58 mln | -$28.34 mln (9 Analysts) |
Q2 Gross Profit |
| $18.90 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Beta Bionics Inc is $20.00, about 26.6% above its July 28 closing price of $15.80
Reuters Recommended Reads
July 29 - Anika Therapeutics Q2 revenue rises, lifts 2026 outlook
July 29 - Integra LifeSciences Q2 revenue slightly beats, adjusted EPS tops estimates
July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)